Investigating how clozapine affects specific subgroups of psychosis patients
2/5-Clozapine Response and Biomarker Correlates in Low-IEA Biotype-1
This study is looking at how certain biological markers can help identify different groups of people with psychosis, especially those who have more severe symptoms and lower cognitive abilities, to see how well they respond to clozapine, a medication that can be very effective but also has some serious side effects, with the hope of personalizing treatment for better results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11093986 on NIH RePORTER |
What this research studies
This research focuses on understanding how different biological markers can help identify subgroups of patients with psychosis, particularly those with low cognition and high symptoms. By analyzing a large library of biomarkers, the study aims to determine how these subgroups respond to clozapine, an antipsychotic medication known for its effectiveness but also for its serious side effects. The goal is to improve diagnostic accuracy and treatment outcomes by tailoring therapies based on individual biological profiles. Patients will be monitored for changes in their symptoms and cognitive function as part of the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with psychosis, particularly those exhibiting low cognitive function and high symptom severity.
Not a fit: Patients who do not have a diagnosis of psychosis or those who do not fall into the specific biomarker-defined subgroups may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with psychosis.
How similar studies have performed: Previous research has shown promise in using biomarkers to define psychosis subgroups, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Gershon, Elliot S — University of Chicago
- Study coordinator: Gershon, Elliot S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.